AVROBIO, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- $5.2M
- Website
- http://tectonictx.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
- Conditions
- Gaucher Disease, Type 3
- Interventions
- Drug: Gene therapyDrug: Enzyme Replacement Agent
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- AVROBIO
- Registration Number
- NCT05815004
Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201
- Conditions
- Fabry Disease
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- AVROBIO
- Target Recruit Count
- 5
- Registration Number
- NCT04999059
- Locations
- 🇦🇺
Royal Melbourne Hospital, Melbourne, Parkville VIC, Australia
🇦🇺Royal Perth Hospital, Perth, Australia
🇧🇷Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02
- Conditions
- Type 1 Gaucher Disease
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- AVROBIO
- Target Recruit Count
- 4
- Registration Number
- NCT04836377
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇨🇦M.A.G.I.C. Clinic Ltd, Calgary, Calgary Alberta, Canada
Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- AVROBIO
- Target Recruit Count
- 8
- Registration Number
- NCT04145037
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- AVROBIO
- Target Recruit Count
- 15
- Registration Number
- NCT03454893
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇦🇺Royal Melbourne Hospital, Melbourne, Parkville VIC, Australia
News
Advancements in Pompe Disease Treatment: A Pipeline Review
• Pompe disease, a rare genetic disorder, is seeing advancements with over 20 therapies in the pipeline. • Key players like Amicus Therapeutics and Spark Therapeutics are developing novel treatments, including gene therapies and enzyme replacements. • Clinical trials are underway, evaluating the safety and efficacy of drugs like Cipaglucosidase alfa and SPK-3006. • These emerging therapies target various mechanisms, such as alpha-glucosidase replacement and glycogen synthase kinase modulation.